iRhythm Technologies provides diagnostic monitoring solutions that facilitate the early diagnosis and treatment of cardiac arrhythmia.
P/E adj.
Net profit (adj.)
P/B
Book value
P/FCF
FCF
Yield
Growth potential
iRhythm Technologies news
06.05.2022
iRhythm Technologies' GAAP loss for 3 months of 2022 was $50.609 million, up 82.2% from $27.779 million in the prior year. Revenue increased 24.3% to $92.378 million from $74.311 million a year earlier.
Source: 
investors.irhythmtech.com
investors.irhythmtech.com
24.02.2022
iRhythm Technologies' GAAP loss for 2021 was $101.361 million, up 2.3 times from $43.83 million in the prior year. Revenue increased 21.7% to $322.825 million from $265.166 million a year earlier.
Source: investors.irhythmtech.com
investors.irhythmtech.com
05.11.2021
The GAAP loss of iRhythm Technologies for 9M 2021 was $68.87 million, having doubled from $34.179 million in the previous year. Revenues increased by 29.3% to $241.021 million compared to $186.357 million a year earlier.
Source: investors.irhythmtech.com
investors.irhythmtech.com
06.08.2021
iRhythm Technologies' GAAP loss for six months of 2021 was $45.139 million, up 53% from $29.502 million in the prior year. Revenue increased 36% to $155.589 million from $114.413 million a year earlier.
Source: investors.irhythmtech.com
investors.irhythmtech.com
General information
| Company name | iRhythm Technologies |
|---|---|
| Tags | #medtech |
| Sector | Health Care / Health Care Equipment & Services / Health Care Equipment & Supplies / Health Care Equipment |
| Business address | 650 TOWNSEND STREET SUITE 500 San Francisco CA 94103 415-632-5700 |
| Mailing address | 650 TOWNSEND STREET SUITE 500 San Francisco CA 94103 |
| Website | www.irhythmtech.com |
| Information disclosure | www.sec.gov |
English (US) 